Today's cholesterol test is about to be disrupted. Finnish startup, Nightingale Health has developed a blood test that collects 50 times more biomarker data than that old test -- and they're offering it to labs at the same price point.
Already the new test is boasting a 20% better prediction rate for diabetes and cardiovascular disease than the traditional test, with more work being done with research institutions and universities to build that evidence base.
The company is working off a $30M round but what's next as they look expand out of Europe and open labs in the US and Asian markets? Hint: They're looking to expand the understanding of the biomarkers their test provides by analyzing 500,000 blood samples from the UK Biobank. Listen in then find out more at www.nightingalehealth.com.